What is the best time to take MOTS-c?

There is no research-backed best time. No human trial has compared morning with night or a dose before exercise with one after it. A provider sets the schedule from the individual prescription, other medications, daily routine, and any symptoms that need monitoring. A precise clock time found online is not the same as a tested human protocol.

Should MOTS-c be taken in the morning or at night?

Neither has been shown better in people. Morning and night have not been compared in a human MOTS-c trial, so claims that one is more effective go beyond the evidence. The prescribing provider may favor a time that fits the prescribed frequency and makes it easier to notice and discuss any time-linked symptoms.

Should MOTS-c be timed before a workout?

Human research does not establish a pre-workout window. The key human study measured a rise in the MOTS-c that participants made naturally during and after exercise; it did not give them the peptide. One experiment administered MOTS-c to six mice 10 minutes before running, but a small animal experiment cannot define a schedule for people.

How long does administered MOTS-c stay in the body?

That has not been established in people. FDA reviewers reported in July 2026 that they found no public human studies tracking how administered MOTS-c moves through the body over time. The four-hour result from the exercise study describes the body’s own circulating MOTS-c returning to baseline, not the clearance of an administered dose.

Who decides a MOTS-c schedule?

The prescribing provider decides. They can account for the prescribed frequency, other medications, exercise and sleep patterns, and symptoms that appear after treatment begins. This matters because no human timing trial provides a standard morning, evening, or workout-based schedule. The plan should come from clinical review, not a mouse protocol copied into a calendar.

When to Take MOTS-c: What Human Research Says

The honest answer to when to take MOTS-c is simple: human research has not established a best time. There is no trial comparing morning with night, or a dose before a workout with one after it. The study people usually cite found that exercise raised the MOTS-c already made by the body. It did not give MOTS-c to participants. A small mouse study did test it shortly before exercise, but that result cannot set a human schedule. If MOTS-c is prescribed, the provider sets the timing.

MOTS-c is a short chain of 16 amino acids, the building blocks of proteins. It is encoded in mitochondrial DNA. Mitochondria are the parts of cells that help turn fuel into usable energy. That biology makes exercise a sensible research question, but it does not tell us what time a prescription belongs on the clock.

When to take MOTS-c: the evidence at a glance

Timing question	What the evidence shows
Morning or night?	No human study has compared them.
Before or after exercise?	No human study has compared timed doses around exercise.
Why is pre-workout timing discussed?	One experiment gave MOTS-c to six mice 10 minutes before a treadmill test.
Does exercise matter to the science?	Yes. A human study found that exercise temporarily raised the MOTS-c made by the body.
Who sets the actual schedule?	The prescribing provider, using the individual prescription and clinical context.

The distinction in the middle of that table matters. Endogenous MOTS-c means MOTS-c made inside the body. Exogenous MOTS-c means MOTS-c given from outside the body. Evidence about one does not automatically answer how to schedule the other.

What the human exercise study actually found

In a 2021 Nature Communications study, researchers followed 10 sedentary, healthy young men through a high-intensity cycling session. They collected blood before, during, just after, and four hours after exercise. They also sampled thigh muscle before, just after, and four hours later.

In this small group, circulating MOTS-c rose about 1.6-fold during exercise and 1.5-fold just after it, then returned to baseline after four hours of rest. MOTS-c in muscle rose 11.9-fold just after exercise and was still elevated four hours later, although it was moving back toward baseline.

Those are measurements of a natural response to exercise. The participants were not given MOTS-c, and the study did not compare dosing schedules. It supports an exercise link. It does not establish a pre-workout window.

Why morning and night are still open questions

A useful timing study would give MOTS-c to people at different times and compare the results, side effects, and how the substance moves through the body. That study has not been published. There is not even a human half-life for administered MOTS-c that could anchor a morning-versus-night recommendation. Half-life means how long it takes the body to clear half of a dose.

As of September 6, 2026, the day this article was written, the FDA presentation prepared for its July 23, 2026 advisory-committee review said the agency had not identified public clinical studies or human exposure data for administered MOTS-c-related bulk substances by any route. It also found no published studies tracking how administered MOTS-c moves through a living body over time. That is the missing information a confident clock-time rule would need.

MOTS-c is not FDA-approved, and the compounded formulation offered here is not FDA-approved. That status is one part of the clinical picture, not a marketing gate: a licensed provider may still prescribe a compounded formulation when they judge it appropriate, and that decision is between the patient and the doctor.

What the mouse studies can and cannot tell us

The 2021 paper also gave mice daily MOTS-c for two weeks before testing their running. That design explored repeated treatment, not whether morning or evening was better.

A separate 2022 study in Physiological Reports came closer to the question people usually ask. Six adult female mice each received MOTS-c or saline 10 minutes before a treadmill test, then crossed over to the other condition 10 days later. After MOTS-c, average running time was 12% longer and distance was 15% greater.

That finding is interesting, but it remains a six-mouse result. The peptide was injected into the abdominal cavity, a route used in animal experiments, and the test did not compare morning with night, before with after, or different timing windows. It cannot be turned into a human schedule.

Why SS-31 does not supply the missing schedule

MOTS-c and SS-31 often appear together because both are discussed in relation to mitochondria. They are different molecules with different mechanisms and different evidence. Research on how SS-31 is studied cannot fill the timing gap for MOTS-c, and using them together would be a separate clinical decision rather than a reason to copy one schedule onto the other.

What a provider can use instead of a made-up rule

Without a human timing trial, a provider is not choosing between a proven morning schedule and a proven evening schedule. They may build a routine around the prescribed frequency, other medications, the person’s exercise and sleep schedule, and whether any symptoms seem tied to the timing. A report of trouble sleeping or a change in energy can be clinically useful without proving that MOTS-c caused it.

Dose and timing are separate questions. The published evidence behind MOTS-c dosage decisions is limited too, so neither should be borrowed from a mouse protocol or an online calendar. Any new or concerning symptom belongs in the conversation with the prescriber; the fuller MOTS-c side-effects guide explains what is known and what remains uncertain.

The practical goal is a schedule the provider can explain and monitor, not a precise-looking routine built from animal data. Morning may fit one prescription. Another schedule may fit someone else. Neither choice has been shown superior in a human trial.

At Promise, a licensed provider reviews every request and sets the timing if MOTS-c is prescribed. Not everyone qualifies. That review is where the research gaps, the rest of the medication list, and the person’s routine get turned into an individual plan.